SARS-CoV-2 3CL-protease inhibitors derived from ML300: investigation of P1 and replacements of the 1,2,3-benzotriazole

Starting from compound 5 (CCF0058981), a structure-based optimization of the P1 subsite was performed against the severe acute respiratory syndrome coronavirus (SARS-CoV-2) main protease (3CL(pro)). Inhibitor 5 and the compounds disclosed bind to 3CL(pro) using a non-covalent mode of action that uti...

Descripción completa

Detalles Bibliográficos
Autores principales: Hooper, Alice, Macdonald, Jonathan D., Reilly, Brenna, Maw, Joshua, Wirrick, Aidan P, Han, Sang Hoon, Lindsey, A. Abigail, Rico, Emma G, Romigh, Todd, Goins, Christopher M, Wang, Nancy S, Stauffer, Shaun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197776/
https://www.ncbi.nlm.nih.gov/pubmed/37214977
http://dx.doi.org/10.21203/rs.3.rs-2880312/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197776/
https://www.ncbi.nlm.nih.gov/pubmed/37214977
http://dx.doi.org/10.21203/rs.3.rs-2880312/v1

Ejemplares similares